Drugs / Quadrivalent RIV with H3 strain 2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04451954 | Jul 2020 → Sep 2021 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 1 | NCT04144179 | Nov 2019 → Feb 2020 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent RIV with H3 strain 2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04144179 ↗ |
| Modality | Vaccine | “quadrivalent recombinant influenza vaccine (RIV) formulations” NCT04144179 ↗ |
| Route | Intramuscular | “Route of administration: Intramuscular” NCT04144179 ↗ |